Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566345 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
A Phase 3 study, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,670
- Enrollment target
NCT00566345: Completed Phase 3 study, sponsored by Alachua Government Services.
NCT00566345 is a Phase 3 study that has completed, run by Alachua Government Services. The registered enrollment target is 3,670 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (375% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566345, a Phase 3 study, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,670 participants
- Enrollment target
Study Summary
The primary purpose of this study is to demonstrate the efficacy of an investigational Vero-cell derived influenza vaccine to prevent infection in an adult population with an influenza virus that is antigenically similar to one of the three strains in the vaccine. All subjects will be randomized to receive a single 0.5 ml intramuscular injection from one of three lots of seasonal Vero-cell derived influenza vaccine or saline placebo. Subjects will be monitored for 180 days following vaccination for occurrence of adverse events. For determining antibody response, subjects will have one blood draw before and one blood draw 21 days after vaccination.
Interventions
- BIOLOGICAL Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)
- OTHER Phosphate buffered saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,670 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00566345 record still lists
NCT00566345 is an interventional study that assigns participants to a tested intervention. Its 3,670 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (375% higher).
The record links to 0 conditions, and to 2 interventions - of which Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) is the first listed.
NCT00566345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00566345 about?
NCT00566345 is a clinical study titled "Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)". The primary purpose of this study is to demonstrate the efficacy of an investigational Vero-cell derived influenza vaccine to prevent infection in an adult population with an influenza virus that is antigenically similar to one of the three strains in the vaccine. All subjects will be randomized to ...
What is the current status of trial NCT00566345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,670 participants. The study started on 2007-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00566345?
The interventions under investigation include: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) (BIOLOGICAL), Phosphate buffered saline (OTHER).
Who is sponsoring clinical trial NCT00566345?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00566345's enrollment target sits among peer trials
3,670 67th of 2000 higher than 1,934 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia